- Forecast Value (2034): 3.03 Bn
- CAGR (2034): 11.5%
Leukocyte Count Testing Market Outlook (2024 to 2034)
The global leukocyte count testing market is analyzed at a value of US$ 1.02 billion in 2024 and is projected to reach a size of US$ 3.03 billion by 2034. Worldwide demand is forecasted to increase at a noteworthy CAGR of 11.5% between 2024 and 2034.
One of the key factors driving the demand for leukocyte count testing is the rising prevalence of infections, including bacterial, viral, and fungal diseases. In hospitals and clinical settings, where timely identification of immune responses is extremely critical for efficient treatment, these tests are especially important for identifying and tracking infections. White blood cell (WBC) levels need to be continuously monitored in chronic disorders, such as sepsis, leukemia, autoimmune diseases, and others to assess the course of the illness and the treatment efficacy. The need for routine leukocyte count testing as part of continuing disease care is driven by this.
Testing is becoming simpler, more accurate, and widely available due to the development of more efficient diagnostic equipment, such as automated leukocyte count testing devices. Lab-on-a-chip technologies and point-of-care devices are increasing the effectiveness of testing, which is contributing to the market expansion. More availability of diagnostic testing is a result of the growing healthcare infrastructure. The market is expanding as more healthcare professionals incorporate leukocyte count tests into standard examinations.
The North American region is estimated to lead with 37.3% of the worldwide leukocyte count testing market in 2024 because of a well-established healthcare infrastructure. Due to its sophisticated healthcare system, which uses leukocyte count testing extensively to diagnose cancer, autoimmune disorders, and infections, the market is expanding in the region. The market in East Asia is expanding at 11.3% CAGR through 2034 due to increasing government focus in several countries on improving healthcare facilities.
Based on product type, the demand for automatic leukocyte count testing is projected to touch US$ 668.66 million in 2024 due to its ability to deliver faster, more accurate, and reliable results compared to manual methods. Automation reduces human error, improves efficiency, and allows for high-throughput testing, making it especially valuable in busy clinical environments where quick diagnosis is crucial.
| Report Attributes | Details |
|---|---|
| Leukocyte Count Testing Market Size (2024E) | US$ 1.02 Billion |
| Forecasted Market Value (2034F) | US$ 3.03 Billion |
| Global Market Growth Rate (2024 to 2034) | 11.5% CAGR |
| North America Market Share (2024E) | 37.3% |
| Western Europe Market Value (2024E) | US$ 224.34 Million |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 13.8% CAGR |
| Automatic Segment Value (2034F) | US$ 2.01 Billion |
| Benchtop Segment Value (2034F) | US$ 1.83 Billion |
| Key Companies Profiled | Hemocue; Unico; Electronics India; Woodley Equipment Company Ltd; Radiometer Medical ApS; Erma Inc.; Shenzhen Prokan Electronics Inc.; NanoEnTek Inc.; Glaswarenfabrik Karl Hecht GmbH & Co KG |
Increasing bacterial infection with the growing adoption of point-of-care devices will witness a promising growth outlook for leukocyte count testing in the long run. Technological advancement in devices for leukocyte testing provides momentum to the leukocyte count testing market with double-digit expected CAGR over forecast years.
What is Driving Demand for Leukocyte count testing?
The increasing prevalence of the chronic disorder, cancer coupled with the growing adoption of digital devices to optimize patient care are the major factors expected to accelerate the market over forecast years. National Cancer Institute recorded that, in the U.S, around 1,735,350 new cases and around 609,640 deaths caused by cancer registered in 2018.
Other factors such as the significant increase in capital investments by the government and medical device manufacturers, technological advancements in mobile healthcare are also expected to propel the leukocyte count testing market in long run.
Besides, the benefits of testing at home, smartphone compatibility, user-friendliness, patient convenience of leukocyte count testing are also anticipated providing an optimistic growth to the market over the upcoming years.
Increasing Usage of Smartphones to Boost Leukocyte count testing Demand
The number of smartphone users is growing at a substantial rate all over the world. For instance, according to ICEA (India Cellular and Electronics Association) report, there were over 500 million smartphone users in India in the year 2019 and this reached 829 million in 2022. Increasing preference for telemedicine and at-home care by the patients and the clinicians is likely to increase the demand for the leukocyte count testing market over the forecast years.
U.S. and Canada Leukocyte count testing Market Outlook
The U.S. is anticipated to be the largest market for leukocyte count testing owing to its high adoption of advanced digital technology, awareness among the patients, well-developed healthcare infrastructure, and supportive government policies. The U.S leukocyte count testing market is witnessing considerable growth going forward.
Like the United States, Canada is also creating big opportunities for the market players in leukocyte count testing product launch and development. Meanwhile, several top United States leukocyte count testing market leaders are expanding their facilities in Canada.
Europe Demand Outlook for Leukocyte count testing
Suitable government policies and regulations for the reimbursement of digital health applications are expected to boost the European leukocyte count testing market over forecast years. In addition, Germany is anticipated to share the largest market in terms of revenue owing to its national reimbursement policies where a significant amount of people are accessing the digital health application in this country.
Who are the Key Manufacturers and Suppliers of Leukocyte count testing?
Some of the leading manufacturers and suppliers of leukocyte count testing include
- Hemocue
- Unico
- Electronics India
- Woodley Equipment Company Ltd
- Radiometer Medical ApS
- Erma Inc.
- Shenzhen Prokan Electronics Inc.
- NanoEnTek Inc.
- Glaswarenfabrik Karl Hecht GmbH & Co KG
Manufacturers in this market engaged in several industry development activities such as a new product launch, collaborations to hold their strong position in the global market. For instance, In March 2019, HemoCue launched an in-office hemoglobin count system in the U.S.
Laboratory Informatics Market Report Highlights
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Segmentation of Leukocyte Count Testing Market Research
-
By Product Type :
- Automatic
- Manual
-
By Modal :
- Benchtop
- Portable
-
By End User :
- Hospitals
- Clinics
- At home
- Others
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
- Frequently Asked Questions -
At what rate is the leukocyte count testing market projected to expand through 2034?
Global demand for leukocyte count testing procedures is evaluated to increase at a CAGR of 11.5% through 2034.
What is driving the demand for leukocyte count testing?
The rising incidence of chronic diseases, such as cancer and the expanding use of digital technologies to improve patient care are boosting sales growth.
Where are leukocyte count testing service providers find potential growth opportunities?
Growing demand in North America with presence of well-established healthcare infrastructure, adoption of digital technologies, and awareness among patients.